VIR supply chain intelligence for Vir Biotechnology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Vir Biotechnology, Inc. (VIR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE | INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE | 92% | Under the terms of the IRB Research Agreement, IRB performs certain research activities for Humabs |
| SANOFI-S-A | SANOFI-S-A | 90% | Under the terms of Vir Bio's licensing agreement with Sanofi, Vir Bio will share a portion of certain collaboration proceeds received from Astellas with Sanofi |
| THE-ROCKEFELLER-UNIVERSITY | THE-ROCKEFELLER-UNIVERSITY | 90% | Pursuant to the Rockefeller Agreement, we entered into an exclusive license agreement with The Rockefeller University, or Rockefeller |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR graph: Reciprocal relationship from ALNY graph: , the lead party will be responsible for all costs and expenses incurred in c… |
| SNY | Sanofi | 72% | Reciprocal relationship from SNY graph: . The license agreement entered into with Vir Biotechnology, Inc. in September 2024 led to the derecognition of the ProXTen intangible asset. For further infor… |
| SNYNF | Sanofi | 72% | candidates, the competitive position of our product candidates, and import or export of raw materials and product used in our drug development, clinical manufacturing and future commercial activities… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: candidates, the competitive positio… |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substant… |
| XNCR | Xencor, Inc. | 72% | Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of Decemb… |
| AAPL | Apple Inc. | 62% | Reciprocal relationship from AAPL graph: Reciprocal relationship from VIR graph: Reciprocal relationship from AAPL graph: Reciprocal relationship from VIR graph: Reciprocal relationship from AAPL gra… |
| BTI | British American Tobacco p.l.c. | 62% | Reciprocal relationship from BTI graph: Reciprocal relationship from VIR graph: Reciprocal relationship from BTI graph: Reciprocal relationship from VIR graph: Reciprocal relationship from BTI graph:… |
| VHC | VirnetX Holding Corporation | 62% | Reciprocal relationship from VHC graph: Reciprocal relationship from VIR graph: Reciprocal relationship from VHC graph: Reciprocal relationship from VIR graph: Reciprocal relationship from VHC graph:… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $65,867,804 across 1 awards. 75A50122C00081 VIR BIOTECHNOLOGY - OTA FOR PRE-EXPOSURE PROPHYLACTIC MONOCLONAL ANTIBODIES FOR THE PREVEN… |
| ASTELLAS-US-LLC | ASTELLAS-US-LLC | 92% | Vir Bio has agreed to grant to Astellas, subject to certain intellectual property rights of Sanofi S.A. (Sanofi), an exclusive license to develop, manufacture, commercialize and otherwise exploit VIR-5500 |
| NORGINE | NORGINE | 92% | The Company determined that Norgine is a customer with respect to the delivery of Norgine License |
| NORGINE-PHARMA-UK-LIMITED | NORGINE-PHARMA-UK-LIMITED | 92% | In exchange, Vir Bio will receive an initial reimbursement of development costs from Norgine in the amount of EUR 55 million and is eligible to receive up to EUR 495 million in clinical, regulatory a… |
| GATES-FOUNDATION | GATES-FOUNDATION | 90% | The Company accounted for the common stock issued to the Gates Foundation based on its fair market value on the closing date |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our some of… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR graph: clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, … |
| SNYNF | Sanofi | 72% | e of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements $ $ Less: Segment expenses (1) Cost of revenue Research and development Personnel (2) Licenses, collaborations and con… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: e of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements $ $ Less: Segment expenses (1) Cost … |
| AMUNIX-PHARMACEUTICALS-INC | AMUNIX-PHARMACEUTICALS-INC | 62% | asonably believes may threaten the success of the project. 105 Table of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements Concurrently with the execution of the grant agreem… |
| BRII-BIOSCIENCES-LIMITED | BRII-BIOSCIENCES-LIMITED | 62% | n our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our l… |
| COMPANY-LLC | COMPANY-LLC | 62% | tive 119,031 174,441 (55,410) Restructuring, long-lived assets impairment and related charges 34,995 13,559 21,436 Total operating expenses 661,370 770,485 (109,115) Loss from operations (587,165) (6… |
| ENCENTRIO-THERAPEUTICS-INC | ENCENTRIO-THERAPEUTICS-INC | 62% | n our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our l… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VIR-DEBT-13359 | Warrants outstanding: 2049000 | 90% | xbrl warrant detail from xbrl 2019-12-31. |
| VIR-DEBT-13360 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| VIR-DEBT | Debt stack $95.6M | 90% | Market cache reports total debt of $95.6M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VIR-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 257 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BTI | British American Tobacco p.l.c. | 100.00 | 1 | ['supplier'] |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AAPL | Apple Inc. | 100.00 | 1 | ['supplier'] |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 |